Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
about
Emerging therapeutic biomarkers in endometrial cancerClinical application of genetics to guide prevention and treatment of oral diseasesIn vitro and in vivo models for analysis of resistance to anticancer molecular therapiesAntitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitorsSerum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.Molecular Mechanisms that Regulate Epidermal Growth Factor Receptor InactivationSurvival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesisDetection of the epidermal growth factor receptor, amphiregulin and epiregulin in formalin-fixed paraffin-embedded human placenta tissue by matrix-assisted laser desorption/ionization mass spectrometry imaging.Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells.EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides.Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitorsIn vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines.Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies.Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors.Profile of erlotinib and its potential in the treatment of advanced ovarian carcinomaStromal EGF and igf-I together modulate plasticity of disseminated triple-negative breast tumors.Detecting and treating cancer with nanotechnology.Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivoReduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatmentAcquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2.Targeting EGFR resistance networks in head and neck cancer.Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma.Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.Efficacy and tolerability of pharmacotherapy options for the treatment of medullary thyroid cancer.Emerging drugs for endometrial cancer.Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells.Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model.IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations.Effects of epidermal growth factor receptor and insulin-like growth factor 1 receptor inhibition on proliferation and intracellular signaling in cutaneous SCCHN: potential for dual inhibition as a therapeutic modality.Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.Anti-EGFR Indocyanine Green-Mitomycin C-Loaded Perfluorocarbon Double Nanoemulsion: A Novel Nanostructure for Targeted Photochemotherapy of Bladder Cancer Cells.Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab.
P2860
Q26865904-0D1F8ED4-ACBA-4AB8-ACD7-E1FD3E92A591Q26999507-65C4E6FE-A09A-4C2E-A2F1-5D9764BDC08EQ27014174-32364744-0B2D-4E9E-89C3-17E89BEABCCEQ28478344-5B127F5B-6B87-4955-ACBE-D7AA04117F52Q34032602-89E622AA-5ED7-47DB-A0D3-57A6034B7266Q34163076-53BD94FF-A97F-4502-810D-07C8082766BDQ34213559-FBD4B275-09C0-4277-809E-CD6AC0D98373Q34586319-5C353A47-D3E7-47BF-8BC0-F3BF9ABD17CBQ34809415-2B37A8EB-9CDC-41BD-8B60-2E809E6C9905Q35108153-C16FF9F9-EDAE-44DE-90E9-FD9B895A1B8BQ35184816-ED0415B4-A01B-418F-8241-98443A0CCCA3Q35212644-AB6F8733-54E8-49E6-BEF9-2CBFA4B210A3Q35212685-AF9C6A14-93E8-4B1B-B1F4-165871F300C9Q36280796-814C33B0-DB64-4527-B3EE-E918CA49DFCDQ36475900-35BFB0E4-1C41-431A-87F0-FDD363C19A20Q36880902-D1D85DCD-EAA4-45AE-BD56-35332B7CABCEQ37086275-7E3092F6-9D90-44D9-9DB7-513E49A55D9FQ37089855-654544BD-608A-4C07-A9F9-091842B8C2EEQ37107787-81C4BC77-04D3-42E8-AA8D-CB56CBFC6B41Q37262314-4A7CED2D-591E-472F-9A72-E4DAA14D7D25Q37279290-9D6A07B2-11EB-4E91-B084-EA64FF0E8C4CQ37405633-4332736C-E58F-45CD-879F-B4B3E29BB584Q37414399-7495D328-AC0A-487F-9D34-E4C626D8386DQ37485865-9C2843DD-D630-4366-9A64-80A7D364CF3BQ38058321-E3E0F543-0E73-4447-B4BE-A2412CC9C987Q38261469-2B6D3610-A431-4A8A-B6E4-325D3AB6ED47Q38798148-2A74D657-B0D1-4DBC-9F04-BB11A127FD4EQ39041660-AE8E8CC0-9594-4DD6-BF6A-95B16AAADE1FQ39101764-80E657D0-50AD-4A33-86D9-D68FF47F7DD9Q39365739-333C1092-7BD9-4AB2-9536-BC0F90B39055Q41878464-C73FE22E-A2C1-47CC-99F7-D06D3247492EQ52559163-42DBB28D-B2F2-425C-AAEE-EEC372E34B8CQ54350258-9386ABD5-AE56-45A7-92C6-64E77C8F080A
P2860
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
@en
type
label
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
@en
prefLabel
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
@en
P2093
P1433
P1476
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
@en
P2093
Floriana Morgillo
Giampaolo Tortora
Maria Anna Bareschino
Roberto Bianco
P304
P356
10.1111/J.1432-0436.2007.00200.X
P577
2007-07-02T00:00:00Z